Research for the Treatment of a ‘Black Sheep’ Cancer Moves to Human Clinical Trials
With $3.5 million in funding from the GI Research Foundation, a team at the MD Anderson Cancer Center explores a...
immunotherapy
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer
VISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse Events...
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11,...
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD...
UTMB Taps DoseMe’s Genetic Biomarker Capabilities for Precision Dosing
Health Science Center to Launch Antibiotic Models for Improved Patient Care; Future Deployment of Wide Range of Models Approved for...
UTMB Taps DoseMe’s Genetic Biomarker Capabilities for Precision Dosing
Health Science Center to Launch Antibiotic Models for Improved Patient Care; Future Deployment of Wide Range of Models Approved for...
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is...
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is...
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass.,...
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)--$CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence...
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)--$CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence...
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
INB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant MUC4 expressing HER2 positive breast...
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG)...
Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma
Four cancer types now included in PeptiCRAd-1 with Pembrolizumab trial: sarcoma, melanoma, triple negative breast cancer and non-small cell lung...
Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (Nasdaq:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology...
Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023
SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of...
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage...
ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease
MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for...
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a...
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
Virtual Event to be held on November 29, 2023 at 4:15 p.m. ETLOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) --...